Togo West - Bristol Myers Independent Director
Director
Hon. Togo Dennis West, Jr., is Lead Independent Director of BristolMyers Squibb Company effective May 5 2015. He was Chairman of TLI Leadership Group, a strategic consulting firm since 2006. From 2004 to 2014, he was Chairman of Noblis, Inc., a nonprofit science and technology company, and a member of the Board of Trustees since 2001. He became Trustee Emeritus of Noblis in September 2014. From 2004 to 2006, Secretary West was the Chief Executive Officer of the Joint Center for Political and Economic Studies, a nonprofit research and public policy institution. He served as Of Counsel to the Washington, D.C. based law firm of Covington Burling from 2000 to 2004. Secretary West served as U.S. Secretary of Veterans Affairs from 1998 to 2000 and as U.S. Secretary of the Army from 1993 to 1997. He is a Director on the Board of MedStar Health and a Trustee on the Council on Foreign Relations. since 2015.
Age: 72Tenure: 8 years
Phone: 212-546-4000
Website: http://www.bms.com
Togo West Latest Insider Activity
Tracking and analyzing the buying and selling activities of Togo West against Bristol Myers pink sheet is an integral part of due diligence when investing in Bristol Myers. Togo West insider activity provides valuable insight into whether Bristol Myers is net buyers or sellers over its current business cycle. Note, Bristol Myers insiders must abide by specific rules, including filing SEC forms every time they buy or sell Bristol Myers'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Togo West over three weeks ago Acquisition by Togo West of 21242 shares of FuelCell Energy subject to Rule 16b-3 |
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Mariasun Larregui | Coty Inc | 57 | |
| Theresa Wagler | CF Industries Holdings | 50 | |
| Robert Kuhbach | CF Industries Holdings | 68 | |
| Hon Lau | Yuexiu Transport Infrastructure | 67 | |
| John Fahey | Lindblad Expeditions Holdings | 66 | |
| Catherine Reynolds | Lindblad Expeditions Holdings | 60 | |
| Anna Makanju | Coty Inc | 44 | |
| Francoise Colpron | Sealed Air | 48 | |
| Javed Ahmed | CF Industries Holdings | 61 | |
| John Eaves | CF Industries Holdings | 63 | |
| Michael Chu | Sealed Air | 69 | |
| John Johnson | CF Industries Holdings | 69 | |
| Edward Schmitt | CF Industries Holdings | 69 | |
| Neil Lustig | Sealed Air | 58 | |
| Paul Brown | Lindblad Expeditions Holdings | N/A | |
| Kenneth Manning | Sealed Air | 73 | |
| Robert Arzbaecher | CF Industries Holdings | 61 | |
| Doi Cheung | Yuexiu Transport Infrastructure | 52 | |
| Jacqueline Kosecoff | Sealed Air | 70 | |
| Henry Keizer | Sealed Air | 63 | |
| Erhard Schoewel | Coty Inc | 71 | |
Bristol-Myers Squibb Leadership Team
Elected by the shareholders, the Bristol Myers' board of directors comprises two types of representatives: Bristol Myers inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol. The board's role is to monitor Bristol Myers' management team and ensure that shareholders' interests are well served. Bristol Myers' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol Myers' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ann Powell, Chief Human Resource Officer, Senior Vice President | ||
| Togo West, Independent Director | ||
| Karen Vousden, Director | ||
| Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics Officer | ||
| Alan Lacy, Independent Director | ||
| Robert Bertolini, Independent Director | ||
| Jose Baselga, Independent Director | ||
| Charles Bancroft, CFO, Executive Vice President | ||
| Gerald Storch, Independent Director | ||
| Louis Schmukler, President - Global Manufacturing and Supply | ||
| Michael Grobstein, Independent Director | ||
| Christopher Boerner, Executive Vice President and Chief Commercial Officer | ||
| John Elicker, Senior Vice President - Public Affairs and Investor Relations | ||
| Anne Nielsen, Senior Vice President Chief Compliance and Ethics Officer | ||
| Karen Santiago, Senior Vice President Controller | ||
| Giovanni Caforio, COO, Director | ||
| Vicki Sato, Independent Director | ||
| Emmanuel Blin, Senior Vice President Chief Strategy Officer | ||
| Joseph Caldarella, Senior Vice President Corporate Controller | ||
| Laurie Glimcher, Independent Director | ||
| Murdo Gordon, Executive Vice President Chief Commercial Officer | ||
| Lamberto Andreotti, CEO, Director | ||
| Thomas Lynch, Independent Director | ||
| Dinesh Paliwal, Independent Director | ||
| Lewis Campbell, Independent Director | ||
| Theodore Samuels, Independent Director | ||
| Samuel Moed, Senior Vice President - Strategic Planning and Analysis | ||
| Matthew Emmens, Independent Director | ||
| Ann Judge, Senior Vice President - Global Human Resources | ||
| Sandra Leung, General Counsel, Corporate Secretary | ||
| Paul Autenried, Senior Vice President - Enterprise Services, CIO | ||
| Francis Cuss, Executive Vice President Chief Scientific Officer | ||
| Paul Biondi, Senior Vice President Head - Business Development | ||
| Peter Arduini, Independent Director |
Bristol Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bristol Myers a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Revenue | 46.38 B | |||
| EBITDA | 20.1 B | |||
| Net Income | 7.01 B | |||
| Cash And Equivalents | 6.07 B | |||
| Cash Per Share | 3.72 X | |||
| Total Debt | 39.6 B | |||
| Debt To Equity | 59.40 % | |||
| Current Ratio | 1.40 X | |||
| Book Value Per Share | 7.55 X | |||
| Cash Flow From Operations | 16.21 B |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Bristol Myers without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Financial Widgets Now
Financial WidgetsEasily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
| All Next | Launch Module |
Pair Trading with Bristol Myers
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to First Horizon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace First Horizon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back First Horizon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling First Horizon National to buy it.
The correlation of First Horizon is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as First Horizon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if First Horizon National moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for First Horizon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Bristol Pink Sheet
If you are still planning to invest in Bristol-Myers Squibb check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bristol Myers' history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |